J.B. Chemicals & Pharmaceuticals (NSE: JBCHEPHARM) has a diversified product portfolio that covers various therapeutic areas such as cardiology, dermatology, gastroenterology, neurology, and diabetology. The company’s major brands include Metrogyl, Rantac, Nicardia, Cilacar, and Chericof. In addition to its prescription drug business, J.B. Chemicals & Pharmaceuticals also has a significant presence in the OTC market in India.
The company has a strong manufacturing base in India, with four state-of-the-art manufacturing facilities that are compliant with international regulatory standards. J.B. Chemicals & Pharmaceuticals is committed to maintaining the highest standards of quality, safety, and environmental sustainability across its operations. J.B. Chemicals & Pharmaceuticals recently reported its quarterly earnings for the period ending December 31, 2022. The company’s consolidated Revenue for the quarter was ₹792.71 crore, up 32% from the same period last year. The company’s EPS for the quarter was ₹13.57, while its Net profit for the quarter was ₹106.10 crore, up 26% YoY.